Puma Biotechnology, Inc. Stock News

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Ince...

ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designe...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performance, Puma's robust dividend growth history and stable payout ratio indicate a solid foundation for future shareholder returns. My DCF analysis reveals that Puma is undervalued, with an intrinsic valu...